Role of the inflammatory response in community-acquired pneumonia: clinical implications

References

• Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet. 2015;386:1–16.
   PubMed Web of Science ®Google Scholar
• Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–79.
   PubMed Web of Science ®Google Scholar
• Millett ERC, Quint JK, Smeeth L, et al. Incidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: A population-based study. PLoS One. 2013;8:1–11.
   Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Epidemiology of community-acquired pneumonia in older adults: A population-based study. Respir Med. 2009;103:309–316.
   PubMed Web of Science ®Google Scholar
• European lung white book [Internet]. [ Cited 2020 Sept 10]. Available from: https://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/
   Google Scholar
• Carratalà J, Fernández-Sabé N, Ortega L, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: A randomized trial in low-risk patients. Ann Intern Med. 2005;142:165–172.
   PubMed Web of Science ®Google Scholar
• Arnold FW, Wiemken TL, Peyrani P, et al.; CAPO authors. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the community-acquired pneumonia organization (CAPO) international cohort study. Respir Med. 2013;107:1101–1111.
   PubMed Web of Science ®Google Scholar
• Simonetti AF, Garcia-Vidal C, Viasus D, et al. Declining mortality among hospitalized patients with community-acquired pneumonia. Clin Microbiol Infect. 2016;22:e1–7.
   PubMed Web of Science ®Google Scholar
• Walden AP, Clarke GM, McKechnie S, et al. Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Crit Care. 2014;18:1–9.
   Web of Science ®Google Scholar
• Garcia-Vidal C, Ardanuy C, Tubau F, et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax. 2010;65:77–81.
   PubMed Web of Science ®Google Scholar
• Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12:153–160.
   PubMed Web of Science ®Google Scholar
• Abelenda-Alonso G, Rombauts A, Gudiol C, et al. Influenza and bacterial coinfection in adults with community-acquired pneumonia admitted to conventional wards: risk factors, clinical features, and outcomes. Open Forum Infect Dis. 2020 Feb 27;7(3):ofaa066
   Google Scholar
• Burk M, El-Kersh K, Saad M, et al. Viral infection in community-acquired pneumonia: A systematic review and meta-analysis. Eur Respir Rev. 2016;25:178–188.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches IJ, Schultz M, Vincent JL, et al. Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med. 2017;43:48–58.
   PubMed Web of Science ®Google Scholar
• MacIntyre CR, Chugtai AA, Barnes M, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a (H1N1)pdm09. BMC Infect Dis. 2018;18:637.
   PubMed Web of Science ®Google Scholar
• Nazareth R, Chasqueira MJ, Rodrigues ML, et al. Respiratory viruses in mechanically ventilated patients: A pilot study. BMC Pulm Med. 2020;20:39.
   PubMed Web of Science ®Google Scholar
• Legoff J, Zucman N, Lemiale V, et al. Clinical significance of upper airway virus detection in critically ill hematology patients. Am J Respir Crit Care Med. 2019;199:518–528.
   PubMed Web of Science ®Google Scholar
• Liapikou A, Ferrer M, Polverino E, et al. Severe community‐acquired pneumonia: validation of the infectious diseases society of America/American thoracic society guidelines to predict an intensive care unit admission. Clin Infect Dis. 2009;48:377–385.
   PubMed Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the american thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200:e45–e67.
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest. 2013;144:999–1007.
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Dominedò C, Ielpo A, et al. Risk and prognostic factors in very old patients with sepsis secondary to community-acquired pneumonia. J Clin Med. 2019;8:961.
   PubMed Web of Science ®Google Scholar
• Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study. Arch Intern Med. 2007;167:1655–1663.
   PubMed Web of Science ®Google Scholar
• Paats MS, Bergen IM, Hanselaar WEJJ, et al. Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia. Eur Respir J. 2013;41:1378–1385.
   PubMed Web of Science ®Google Scholar
• Antunes G, Evans SA, Lordan JL, et al. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J. 2002;20:990–995.
   PubMed Web of Science ®Google Scholar
• Fernandez-Botran R, Uriarte SM, Arnold FW, et al. Contrasting inflammatory responses in severe and non-severe community-acquired pneumonia. Inflammation. 2014;37:1158–1166.
   PubMed Web of Science ®Google Scholar
• Menéndez R, Montull B, Reyes S, et al. Pneumonia presenting with organ dysfunctions: causative microorganisms, host factors and outcome. J Infect. 2016;73:419–426.
   PubMed Web of Science ®Google Scholar
• Seymour CW, Yende S, Scott MJ, et al. Metabolomics in pneumonia and sepsis: an analysis of the GenIMS cohort study. Intensive Care Med. 2013;39:1423–1434.
   PubMed Web of Science ®Google Scholar
• Siljan WW, Holter JC, Nymo SH, et al. Cytokine responses, microbial aetiology and short-term outcome in community-acquired pneumonia. Eur J Clin Invest. 2018;48:e12865.
   PubMed Web of Science ®Google Scholar
• Lacoma A, Bas A, Tudela P, et al. Correlation of inflammatory and cardiovascular biomarkers with pneumonia severity scores. Enferm Infecc Microbiol Clin. 2014;32:140–146.
   PubMed Web of Science ®Google Scholar
• Fernández-Serrano S, Dorca J, Coromines M, et al. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol. 2003;10:813–820.
   PubMedGoogle Scholar
• Moore LJ, Pridmore AC, Dower SK, et al. Penicillin enhances the toll‐like receptor 2–mediated proinflammatory activity of Streptococcus pneumoniae. J Infect Dis. 2003;188:1040–1048.
   PubMed Web of Science ®Google Scholar
• Ginsburg I. The role of bacteriolysis in the pathophysiology of inflammation, infection and post-infectious sequelae. APMIS. 2002;110:753–770.
   PubMed Web of Science ®Google Scholar
• Orihuela CJ, Maus UA, Brown JS. Can animal models really teach us anything about pneumonia? Eur Respir J. 2020;55:1901539.
   PubMedGoogle Scholar
• Borsa N, Di Pasquale M, Restrepo MI. Animal Models of Pneumococcal pneumonia. Int J Mol Sci. 2019;20:4220.
   PubMed Web of Science ®Google Scholar
• Feldman C, Munro NC, Jeffery PK, et al. Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo. Am J Respir Cell Mol Biol. 1991;5:416–423.
   PubMed Web of Science ®Google Scholar
• Sandgren A, Albiger B, Orihuela CJ, et al. Virulence in mice of pneumococcal clonal types with known invasive disease potential in humans. J Infect Dis. 2005;192:791–800.
   PubMed Web of Science ®Google Scholar
• Hava DL, Camilli A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol Microbiol. 2002;45:1389–1406.
   PubMed Web of Science ®Google Scholar
• Quinton LJ, Walkey AJ, Mizgerd JP. Integrative physiology of pneumonia. Physiol Rev. 2018;98:1417–1464.
   PubMed Web of Science ®Google Scholar
• Kamata H, Yamamoto K, Wasserman GA, et al. Epithelial cell-derived secreted and transmembrane 1a signals to activated neutrophils during pneumococcal pneumonia. Am J Respir Cell Mol Biol. 2016;55:407–418.
   PubMed Web of Science ®Google Scholar
• Taylor PR, Martinez-Pomares L, Stacey M, et al. Macrophage receptors and immune recognition. Annu Rev Immunol. 2005;23:901–944.
   PubMed Web of Science ®Google Scholar
• Mizgerd JP. Inflammation and pneumonia: why are some more susceptible than others? Clin Chest Med. 2018;39:669–676.
   PubMed Web of Science ®Google Scholar
• Alcamo E, Mizgerd JP, Horwitz BH, et al. Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-kappa B in leukocyte recruitment. J Immunol. 2001;167:1592–1600.
   PubMed Web of Science ®Google Scholar
• Balamayooran G, Batra S, Fessler MB, et al. Mechanisms of neutrophil accumulation in the lungs against bacteria. Am J Respir Cell Mol Biol. 2010;43:5–16.
   PubMed Web of Science ®Google Scholar
• Mizgerd JP. Pathogenesis of severe pneumonia: advances and knowledge gaps. Curr Opin Pulm Med. 2017;23:193–197.
   PubMed Web of Science ®Google Scholar
• Colaço HG, Barros A, Neves-Costa A, et al. Host-dependent induction of disease tolerance to infection by tetracycline antibiotics. BioRxiv. 2019. [Pre-print]. DOI:10.1101/833269.
   Google Scholar
• Figueiredo N, Chora A, Raquel H, et al. Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity. 2013;39:874–884.
   PubMed Web of Science ®Google Scholar
• Beura LK, Hamilton SE, Bi K, et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature. 2016;532:512–516.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang B, Guo Y, et al. Cross-protective mucosal immunity mediated by memory Th17 cells against Streptococcus pneumoniae lung infection. Mucosal Immunol. 2017;10:250–259.
   PubMed Web of Science ®Google Scholar
• Martin MD, Danahy DB, Hartwig SM, et al. Revealing the complexity in CD8 T cell responses to infection in inbred c57b/6 versus outbred swiss mice. Front Immunol. 2017;8:1527.
   PubMed Web of Science ®Google Scholar
• Martin MD, Sompallae R, Winborn CS, et al. Diverse CD8 T cell responses to viral infection revealed by the collaborative cross. Cell Rep. 2020;31:107508.
   PubMed Web of Science ®Google Scholar
• Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol. 2017;10:299–306.
   PubMed Web of Science ®Google Scholar
• Wu BG, Segal LN. The lung microbiome and its role in pneumonia. Clin Chest Med. 2018;39:677–689.
   PubMed Web of Science ®Google Scholar
• Yang D, Xing Y, Song X, et al. The impact of lung microbiota dysbiosis on inflammation. Immunology. 2020;159:156–166.
   PubMed Web of Science ®Google Scholar
• Dickson RP, Erb-Downward JR, Huffnagle GB. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med. 2014;2:238–246.
   PubMed Web of Science ®Google Scholar
• Zemans RL, Colgan SP, Downey GP. Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol. 2009;40:519–535.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol. 2007;5:577–582.
   PubMed Web of Science ®Google Scholar
• Ebrahimi F, Giaglis S, Hahn S, et al. Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial. Eur Respir J. 2018;51:1701389.
   PubMed Web of Science ®Google Scholar
• Levi M, Van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38–44
   PubMed Web of Science ®Google Scholar
• Salluh JIF, Verdeal JC, Mello GW, et al. Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med. 2006;32:595–598.
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Musher DM, Shachkina S, et al. Acute pneumonia and the cardiovascular system. Lancet. 2013;381:496–505.
   PubMed Web of Science ®Google Scholar
• Feldman C, Anderson R. Prevalence, pathogenesis, therapy, and prevention of cardiovascular events in patients with community-acquired pneumonia. Pneumonia. 2016;8:1–10.
   Web of Science ®Google Scholar
• Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. N Engl J Med. 2019;380:171–176.
   PubMed Web of Science ®Google Scholar
• Cangemi R, Casciaro M, Rossi E, et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol. 2014;64:1917–1925.
   PubMed Web of Science ®Google Scholar
• Cangemi R, Pignatelli P, Carnevale R, et al. Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. J Infect. 2016;73:107–114.
   PubMed Web of Science ®Google Scholar
• Pignatelli P, Pastori D, Carnevale R, et al. Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. Thromb Haemost. 2015;113:617–624.
   PubMed Web of Science ®Google Scholar
• Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: A prospective cohort study. Lancet Respir Med. 2016;4:259–271.
   PubMed Web of Science ®Google Scholar
• Bermejo-Martin JF, Cilloniz C, Mendez R, et al. Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality. EBioMedicine 2017;24:231–6
   Google Scholar
• De la Torre MC, Palomera E, Serra-Prat M, et al. IgG2 as an independent risk factor for mortality in patients with community-acquired pneumonia. J Crit Care.2016;35:115–9
   PubMed Web of Science ®Google Scholar
• Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6:782–792.
   PubMed Web of Science ®Google Scholar
• Bermejo-Martin JF, Martin-Loeches I, Rello J, et al. Host adaptive immunity deficiency in severe pandemic influenza. Crit Care. 2010;14:R167.
   PubMed Web of Science ®Google Scholar
• Almansa R, Socias L, Ramirez P, et al. Imbalanced pro- and anti-Th17 responses (IL-17/granulocyte colony-stimulating factor) predict fatal outcome in 2009 pandemic influenza. Crit Care. 2011;15:448.
   PubMed Web of Science ®Google Scholar
• Menéndez R, Sahuquillo-Arce JM, Reyes S, et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest. 2012;141:1537–1545.
   PubMed Web of Science ®Google Scholar
• Zobel K, Martus P, Pletz MW, et al. Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ. BMC Pulm Med. 2012;12:6.
   PubMed Web of Science ®Google Scholar
• Menéndez R, Méndez R, Aldás I, et al. Community-acquired pneumonia patients at risk for early and long-term cardiovascular events are identified by cardiac biomarkers. Chest. 2019;156:1080–1091.
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250.
   PubMed Web of Science ®Google Scholar
• Lim WS, Van Der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382.
   PubMed Web of Science ®Google Scholar
• Charles PGP, Wolfe R, Whitby M, et al. SMART‐COP: A tool for predicting the need for intensive respiratory or vasopressor support in community‐acquired pneumonia. Clin Infect Dis. 2008;47:375–384.
   PubMed Web of Science ®Google Scholar
• Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012;16:R141.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 2011;37:1409–1420.
   PubMed Web of Science ®Google Scholar
• Viasus D, Del Rio-Pertuz G, Simonetti AF, et al. Biomarkers for predicting short-term mortality in community-acquired pneumonia: A systematic review and meta-analysis. J Infect. 2016;72:273–282.
   PubMed Web of Science ®Google Scholar
• Kamat IS, Ramachandran V, Eswaran H, et al. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70:538–542.
   PubMed Web of Science ®Google Scholar
• Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379:236–249.
   PubMed Web of Science ®Google Scholar
• Méndez R, Aldás I, Menéndez R. Biomarkers in community-acquired pneumonia (Cardiac and non-cardiac). J Clin Med. 2020;9:549.
   PubMed Web of Science ®Google Scholar
• Sungurlu S, Balk RA. The role of biomarkers in the diagnosis and management of pneumonia. Clin Chest Med. 2018;39:691–701.
   PubMed Web of Science ®Google Scholar
• Savvateeva EN, Rubina AY, Gryadunov DA. Biomarkers of community-acquired pneumonia: A key to disease diagnosis and management. Biomed Res Int. 2019;2019:1701276.
   PubMed Web of Science ®Google Scholar
• Gesell Salazar M, Neugebauer S, Kacprowski T, et al. Association of proteome and metabolome signatures with severity in patients with community-acquired pneumonia. J Proteomics. 2020;214:103627.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ning P, Luo Q, et al. Inflammatory responses relate to distinct bronchoalveolar lavage lipidome in community-acquired pneumonia patients: A pilot study. Respir Res. 2019;20:82.
   PubMed Web of Science ®Google Scholar
• Ning P, Zheng Y, Luo Q, et al. Metabolic profiles in community-acquired pneumonia: developing assessment tools for disease severity. Crit Care. 2018;22:130.
   PubMed Web of Science ®Google Scholar
• Sharma NK, Tashima AK, Brunialti MKC, et al. Proteomic study revealed cellular assembly and lipid metabolism dysregulation in sepsis secondary to community-acquired pneumonia. Sci Rep. 2017;7:1–13.
   PubMed Web of Science ®Google Scholar
• Brouwer MC, Mcintyre P, Prasad K, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Re. 2015;2016:CD004405.
   Google Scholar
• Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267–276.
   PubMed Web of Science ®Google Scholar
• Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378:809–818.
   PubMed Web of Science ®Google Scholar
• Venkatesh B, Finfer S, Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378:797–808.
   PubMed Web of Science ®Google Scholar
• Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. Am J Respir Crit Care Med. 2005;171:242–248.
   PubMed Web of Science ®Google Scholar
• Ridgeon EE, Young PJ, Bellomo R, et al. The fragility index in multicenter randomized controlled critical care trials. Crit Care Med. 2016;44:1278–1284.
   PubMed Web of Science ®Google Scholar
• Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. JAMA. 2015;313:677–686.
   PubMed Web of Science ®Google Scholar
• Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385:1511–1518.
   PubMed Web of Science ®Google Scholar
• Urwyler SA, Blum CA, Coslovsky M, et al. Cytokines and Cortisol – predictors of treatment response to corticosteroids in community-acquired pneumonia? J Intern Med. 2019;286:75–87.
   PubMed Web of Science ®Google Scholar
• Lloyd M, Karahalios A, Janus E, et al. Effectiveness of a bundled intervention including adjunctive corticosteroids on outcomes of hospitalized patients with community-acquired pneumonia: a stepped-wedge randomized clinical trial. JAMA Intern Med. 2019;179:1052–1060.
   PubMed Web of Science ®Google Scholar
• Cangemi R, Falcone M, Taliani G, et al. Corticosteroid use and incident myocardial infarction in adults hospitalized for community-acquired pneumonia. Ann Am Thorac Soc. 2019;16:91–98.
   PubMed Web of Science ®Google Scholar
• Violi F, Calvieri C, Cangemi R. Effect of corticosteroids on myocardial injury among patients hospitalized for community-acquired pneumonia: rationale and study design. The colosseum trial. Intern Emerg Med. 2020;15:79–86.
   PubMed Web of Science ®Google Scholar
• Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2017;12:CD007720.
   PubMedGoogle Scholar
• Nafae RM, Ragab MI, Amany FM, et al. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc. 2013;62:439–445.
   Google Scholar
• Briel M, Spoorenberg SMC, Snijders D, et al. Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis. Clin Infect Dis. 2018;66:346–354.
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1451–1457.
   PubMed Web of Science ®Google Scholar
• Montaner JSG, Lawson LM, Levitt N, et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990;113:14–20.
   PubMed Web of Science ®Google Scholar
• Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Sys. Rev. 2015;2015:CD006150.
   PubMedGoogle Scholar
• Ding L, Huang H, Wang H, et al. Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies. Ann Intensive Care. 2020;10:34.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020. DOI: 10.1056/NEJMoa2021436.
   Web of Science ®Google Scholar
• Moreno G, Rodríguez A, Reyes LF, et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med. 2018;44:1470–1482.
   PubMed Web of Science ®Google Scholar
• Lansbury LE, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis. Crit Care Med. 2020;48:e98–e106.
   PubMed Web of Science ®Google Scholar
• Delaney JW, Pinto R, Long J, et al. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. Crit Care. 2016;20:75.
   PubMed Web of Science ®Google Scholar
• Snijders D, Daniels JMA, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181:975–982.
   PubMed Web of Science ®Google Scholar
• Wirz SA, Blum CA, Schuetz P, et al. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. Eur Respir J. 2016;48:1150–1159.
   PubMed Web of Science ®Google Scholar
• Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977–987.
   PubMed Web of Science ®Google Scholar
• Jacobson JR, Barnard JW, Grigoryev DN, et al. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol - Lung Cell Mol Physiol. 2005;288:L1026–32.
   PubMed Web of Science ®Google Scholar
• Shyamsundar M, McKeown STW, O’Kane CM, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med. 2009;179:1107–1114.
   PubMed Web of Science ®Google Scholar
• Wildes TJ, Grippin A, Fasanya H, et al. Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: the StatVax randomized clinical trial. Vaccine. 2019;37:1313–1324.
   PubMed Web of Science ®Google Scholar
• Havers F, Bramley AM, Finelli L, et al. Statin use and hospital length of stay among adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2016;62:1471–1478.
   PubMed Web of Science ®Google Scholar
• Viasus D, Garcia-Vidal C, Simonetti AF, et al. The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: A randomised, double-blind, placebo-controlled trial. BMJ Open. 2015;5:e006251.
   PubMed Web of Science ®Google Scholar
• McAuley DF, Laffey JG, O’Kane CM, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371:1695–1703.
   PubMed Web of Science ®Google Scholar
• Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6:691–698.
   PubMed Web of Science ®Google Scholar
• Sapey E, Patel JM, Greenwood H, et al. Simvastatin improves neutrophil function and clinical outcomes in pneumonia a pilot randomized controlled clinical trial. Am J Respir Crit Care Med. 2019;200:1282–1293.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Ziesenitz VC, Curtis N, et al. The immunomodulatory effects of macrolides-A systematic review of the underlying mechanisms. Front Immunol. 2018;9:302.
   PubMed Web of Science ®Google Scholar
• Kovaleva A, Remmelts HHF, Rijkers GT, et al. Immunomodulatory effects of macrolides during community-acquired pneumonia: A literature review. J Antimicrob Chemother. 2012;67:530–540.
   PubMed Web of Science ®Google Scholar
• Lorenzo MJ, Moret I, Sarria B, et al. Lung inflammatory pattern and antibiotic treatment in pneumonia. Respir Res. 2015;16:1–8.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Boersma W, Lonergan M, et al. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir Med. 2019;7:845–854.
   PubMed Web of Science ®Google Scholar
• Lee JS, Giesler DL, Gellad WF, et al. Antibiotic therapy for adults hospitalized with community-acquired pneumonia a systematic review. JAMA. 2016;315:593–602.
   PubMed Web of Science ®Google Scholar
• Nie W, Li B, Xiu Q. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:1441–1446.
   PubMed Web of Science ®Google Scholar
• Horita N, Otsuka T, Haranaga S, et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis. Respirology. 2016;21:1193–1200.
   PubMed Web of Science ®Google Scholar
• Sligl WI, Asadi L, Eurich DT, et al. Macrolides and mortality in critically Ill patients with community-acquired pneumonia: A systematic review and meta-analysis. Crit Care Med. 2014;42:420–432.
   PubMed Web of Science ®Google Scholar
• Postma DF, Van Werkhoven CH, Van Elden LJR, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312–1323.
   PubMed Web of Science ®Google Scholar
• Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174:1894–1901.
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881–1890.
   PubMed Web of Science ®Google Scholar
• Shankar-Hari M, Spencer J, Sewell WA, et al. Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care. 2011;16:206.
   Web of Science ®Google Scholar
• De la Torre MC, Torán P, Serra-Prat M, et al. Serum levels of immunoglobulins and severity of community-acquired pneumonia. BMJ Open Respir Res. 2016;3:1–7.
   Web of Science ®Google Scholar
• Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007;35:2693–2701.
   PubMed Web of Science ®Google Scholar
• Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013;2013:CD001090.
   PubMedGoogle Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–377.
   PubMed Web of Science ®Google Scholar
• Tagami T, Matsui H, Fushimi K, et al. Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study. Clin Infect Dis. 2015;61:385–392.
   PubMed Web of Science ®Google Scholar
• Welte T, Dellinger RP, Ebelt H, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med. 2018;44:438–448.
   PubMed Web of Science ®Google Scholar
• Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med. 2000;28:S31–3.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Laterre PF, Francois B, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med. 2011;183:1561–1568.
   PubMed Web of Science ®Google Scholar
• Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055–2064.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Francois B, Zabolotskikh I, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA. 2019;321:1993–2002.
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Cangemi R, et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc. 2015;4:e001595.
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Shindo Y, et al. A hypothesis-generating study of the combination of aspirin plus macrolides in patients with severe community-acquired pneumonia. Antimicrob Agents Chemother. 2019;63:e01556–18.
   PubMed Web of Science ®Google Scholar
• Kor DJ, Carter RE, Park PK, et al. Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department the LIPS-a randomized clinical trial. JAMA. 2016;315:2406–2414.
   PubMed Web of Science ®Google Scholar
• Oz F, Gul S, Kaya MG, et al. Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial. Coron Artery Dis. 2013;24:231–237.
   PubMed Web of Science ®Google Scholar
• Klok FA, Kruip MJHA, Van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147.
   PubMed Web of Science ®Google Scholar
• Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–1099.
   PubMed Web of Science ®Google Scholar
• Henry BD, Neill DR, Becker KA, et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol. 2015;33:81–88.
   PubMed Web of Science ®Google Scholar
• Laterre PF, Colin G, Dequin PF, et al. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2019;19:620–630.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ju Y, Ma Y, et al. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia. Medicine (Baltimore). 2018;97:e13087.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Pachón J, Carratalà J, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clin Microbiol Infect. 2020;S1198–743X. DOI:10.1016/j.cmi.2020.08.010.
   Web of Science ®Google Scholar
• Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2:e474–84.
   PubMedGoogle Scholar
• [cited 2020 Aug 27]. Available from: https://www.roche.com/investors/updates/inv-update- 2020-07-29.htm
   Google Scholar
• Peters van Ton AM, Kox M, Abdo WF, et al. Precision immunotherapy for sepsis. Front Immunol. 2018;9:1926.
   PubMed Web of Science ®Google Scholar
• Velho TR, Santos I, Póvoa P, et al. Sepsis: the need for tolerance not complacency. Swiss Med Wkly. 2016;146:w14276.
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science. 2012;335:936–941.
   PubMed Web of Science ®Google Scholar
• Soares MP, Teixeira L, Moita LF. Disease tolerance and immunity in host protection against infection. Nat Rev Immunol. 2017;17:83–96.
   PubMed Web of Science ®Google Scholar